Manufacturers on opposite sides of the debate around state biosimilar substitution legislation say they consider a Massachusetts law allowing pharmacists to substitute interchangeable biosimilars and notify prescribers automatically through electronic health records as a potential path forward for ongoing discussions regarding the issue. The Generic Pharmaceutical Association -- which has opposed legislation requiring prescriber notification, but supports the new Massachusetts law -- said it hopes other states will adopt similar legislation. Last week GPhA joined the Biotechnology Industry Organization and...